CLS participates in World Conference of Interventional Oncology 8-11 June in Boston, USA

Clinical Laserthermia Systems (CLS) (publ), is participating in WCIO 2017 (World Conference of Interventional Oncology) in Boston, USA.

-   This is the first time we are part of this conference, targeting one of our main user groups, interventional oncologists, said Dan Mogren, CCO at CLS. WCIO 2017 is an excellent forum for us to showcase our products and further expand our presence in the US market, said Dan Mogren.

CLS develops and markets the TRANBERG®|Thermal Therapy System, as well as disposable materials and methods for heat-induced immunotherapy for safe and gentle treatment of cancerous tumors. CLS’ products are marketed in the US for MRI-guided laser ablation.

In May the company announced that the first three patients, diagnosed with early stage prostate tumor disease, had received treatment at The Department of Radiology at University of Texas Medical Branch (UTMB) using CLS single use products.

In the beginning of this year CLS sold its first TRANBERG-system to a leading American cancer clinic, and just recently the company received its first order for its diffusor fiber from the same clinic.

World Conference of Interventional Oncology is held in Boston, USA, 8-11 June. Visit CLS Americas Inc. in booth #305. Read more.

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail:  lee@clinicallaser.se

Tags:

Subscribe

Quotes

This is the first time we are part of this conference, targeting one of our main user groups, interventional oncologists. WCIO 2017 is an excellent forum for us to showcase our products and further expand our presence in the US market.
Dan Mogren, CCO at CLS